Medtronic taps Viz.ai to help equip stroke centers with AI diagnostics

Medical-device giant Medtronic is partnering with Viz.ai to offer stroke centers capabilities for automatically flagging large vessel occlusions while the patient is still on the bed of a CT scanner.

Such occlusions, or LVOs, are strokes caused by a blockage in one of the major arteries of the brain. If not caught quickly, LVOs may lead to permanent neurological impairment.

Medtronic announced the partnership Monday, saying it will distribute Viz.ai’s existing LVO detection and triage software services.

The software is already in use in more than 200 hospitals, and the companies hope to make it available to every stroke center in the U.S., according to the announcement.

Since it connects directly to CT scanners, the software can quickly alert stroke specialists with the images and a HIPAA-compliant call to action sent straight to physicians’ smartphones.  

In preparing the announcement, Medtronic obtained a quote from Elad Levy, MD, chair of neurosurgery at the University of Buffalo’s Jacobs School of Medicine.

The Viz.ai LVO software “facilitates synchronization of stroke care with great potential to impactfully reduce door-to-needle time and help an increased number of patients,” says Levy, who has no financial ties to Viz.ai, according to the announcement.

Medtronic, which markets a device that retrieves blood clots in patients suffering a stroke due to an LVO, notes that stroke is the top cause of disability in the U.S.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.